<DOC>
	<DOCNO>NCT01313962</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetic profile flufirvitide-3 nasal spray healthy subject .</brief_summary>
	<brief_title>Safety Study Flufirvitide-3 Nasal Spray Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Provision sign date , write informed consent prior studyspecific procedure . Subjects must able understand willing comply study procedure , restriction , requirement . Healthy male nonfertile female subject age 18 55 year inclusive Female subject must negative urine pregnancy test screening must lactate breastfeed must nonchildbearing potential Male subject willing use barrier contraception sexual intercourse , Body weight 50 100 kg inclusive body mass index ( BMI ) 18 30 kg/m2 inclusive . Clinically nonsignificant finding physical examination relation age . Negative Rapid Flu Test ( TRU FLUÂ® kit ) Negative nasal examination upon admission study center . History and/or presence clinically significant disease disorder cardiovascular , pulmonary , renal , hepatic , neurological , gastrointestinal psychiatric/mental disease/disorders , History and/or presence hepatic renal disease condition know interfere absorption , distribution , metabolism , excretion drug . Subjects surgical history gastrointestinal tract also exclude participation study . Any clinically significant illness , medical/surgical procedure , trauma within 4 week administration investigational product symptomatic enough affect study conduct wellbeing subject History and/or presence asthma recurrent sinusitis . Active rhinitis screen upon admission study center . Any clinically significant nasal septum deviation , presence septum perforation , history recurrent epistaxis nasal polyp . Subjects history sinus surgery and/or persistent hypertrophic inferior turbinate . History vaccination live vaccine within 7 day attenuate vaccine within 14 day administration investigational product . Any clinically significant abnormality clinical laboratory safety assessment result A positive result screen serum hepatitis B surface antigen , hepatitis C antibodies HIV antibody . Significant orthostatic reaction screen upon admission study center judge Principal Investigator . Abnormal vital sign , 5 minute supine rest , Any clinically significant abnormality rhythm , conduction , morphology rest electrocardiogram ( ECG ) may interfere interpretation QTc interval change . Prolonged QTcF great 450 m shorten QTcF le 360 m family history long QT syndrome . Known suspected drug abuse alcohol abuse dependence Positive screen drug abuse alcohol screen upon admission study center . Excessive intake caffeinecontaining food beverage within 48 hour prior admission study center . Use drug enzymeinducing property St John 's Wort , within 3 week prior administration investigational product . Abstain smoke 30 day prior screen duration study . Use prescribed medication well overthecounter/non prescribed/ herbal medicine , within 2 week prior administration investigational product . Use nasal steroid 3 month prior administration investigational product . Involvement plan and/or conduct study Have receive another new chemical entity participate clinical study include drug treatment within 3 month prior administration investigational product study . Previous randomization treatment present study study Flufirvitide3 . Plasma donation within 4 week prior enrollment blood donation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>antiviral</keyword>
	<keyword>intranasal</keyword>
	<keyword>influenza</keyword>
</DOC>